The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has ...

Recent research has opened the debate on whether chemical imbalances cause depression, anxiety, and other conditions ...

Early clinical proof-of-concept for WEE1 inhibitor APR-1051 in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutationClinical team ...

Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in ...

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced ...

The therapeutic landscape for cutaneous T-cell lymphoma (CTCL) is undergoing a significant shift with the emergence of denileukin diftitox (Lymphir), the first systemic treatment ...

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update Phase 2 interim results suggest treatment with active immunotherapy ACI-7104 may slow the progression of Parkinson's ...

Introduction Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application.

Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...

Barclays 28th Annual Global Healthcare Conference March 11, 2026 10:30 AM EDTCompany ParticipantsSanjiv Patel - ...

Received FDA clearance of Investigational New Drug application (IND) for PRT12396, mutant-selective JAK2V617F inhibitor in the first quarter of 2026 Phase 1 study of PRT12396 in patients with ...

LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 – – $172.1 ...